These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18024093)

  • 1. Biomarkers in drug discovery and development.
    Bakhtiar R
    J Pharmacol Toxicol Methods; 2008; 57(2):85-91. PubMed ID: 18024093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promises of biomarkers in drug development--a reality check.
    Marrer E; Dieterle F
    Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Qualification of imaging biomarkers for oncology drug development.
    Waterton JC; Pylkkanen L
    Eur J Cancer; 2012 Mar; 48(4):409-15. PubMed ID: 22226478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using imaging biomarkers to accelerate drug development and clinical trials.
    Pien HH; Fischman AJ; Thrall JH; Sorensen AG
    Drug Discov Today; 2005 Feb; 10(4):259-66. PubMed ID: 15708744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers: a valuable tool in clinical research and medical practice.
    Carini C
    IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges of biomarkers in drug discovery and development.
    Goodsaid F
    Expert Opin Drug Discov; 2012 Jun; 7(6):457-61. PubMed ID: 22471322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The promise of imaging biomarkers.
    Drug News Perspect; 2010 Mar; 23(2):119-23. PubMed ID: 20369077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development.
    Peck RW
    Drug Discov Today; 2007 Apr; 12(7-8):289-94. PubMed ID: 17395088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular approaches to the identification of biomarkers of exposure and effect--report of an expert meeting organized by COST Action B15. November 28, 2003.
    Gundert-Remy U; Dahl SG; Boobis A; Kremers P; Kopp-Schneider A; Oberemm A; Renwick A; Pelkonen O
    Toxicol Lett; 2005 Apr; 156(2):227-40. PubMed ID: 15737486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optical imaging in drug discovery and diagnostic applications.
    Licha K; Olbrich C
    Adv Drug Deliv Rev; 2005 Jun; 57(8):1087-108. PubMed ID: 15908041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In biomarkers we trust?
    Baker M
    Nat Biotechnol; 2005 Mar; 23(3):297-304. PubMed ID: 15765081
    [No Abstract]   [Full Text] [Related]  

  • 12. General overview: biomarkers in neuroscience research.
    Filiou MD; Turck CW
    Int Rev Neurobiol; 2011; 101():1-17. PubMed ID: 22050846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel genomic methods for drug discovery and mechanism-based toxicological assessment.
    Gant TW; Zhang SD; Taylor EL
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):72-80. PubMed ID: 19152215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New science-based endpoints to accelerate oncology drug development.
    Kelloff GJ; Sigman CC
    Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional genomics and proteomics in the clinical neurosciences: data mining and bioinformatics.
    Phan JH; Quo CF; Wang MD
    Prog Brain Res; 2006; 158():83-108. PubMed ID: 17027692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery.
    Thomas CE; Will Y
    Expert Opin Drug Discov; 2012 Feb; 7(2):109-22. PubMed ID: 22468913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proteomics bottleneck: strategies for preliminary validation of potential biomarkers and drug targets.
    Bodovitz S; Joos T
    Trends Biotechnol; 2004 Jan; 22(1):4-7. PubMed ID: 14690616
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug safety testing paradigm, current progress and future challenges: an overview.
    Ahuja V; Sharma S
    J Appl Toxicol; 2014 Jun; 34(6):576-94. PubMed ID: 24777877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular imaging to biomarker development in neuroscience.
    Frost JJ
    Ann N Y Acad Sci; 2008 Nov; 1144():251-5. PubMed ID: 19076382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.